Titan[269) group with no statistical difference noted for the Pubic phalloplasty (PP, CX[65, Titan[49) and anterolateral thigh phalloplasty (ALT, CX [2, Titan[13) groups. It was noted that there was considerable delay between the time that mechanical failure was confirmed to when the device was explanted and replaced which would account for the explant rates not showing a difference between devices. Further analysis on the 20 Ambicor devices since 2001 revealed a mechanical failure rate of 60% at 7.7 years which is worse than the 3-piece devices.
INTRODUCTION AND OBJECTIVES: Inflatable penile implants are used for treating erectile dysfunction. The AMS 700ä (AMS) implant is coated with a blend of rifampin and minocycline (InhibiZone). TitanÒ Coloplast (Coloplast) soaked in Rifampin/Gentamicin is comparable to AMS in preventing E. coli infection with in vitro studies. Intra-operative soaking of the implant with Bupivacaine is proposed as a strategy for pain control. However, no study has shown if this agent affects the protective effect of InhibiZone in AMS and/or of Rifampin/Gentamicin soaked Coloplast. We tested the hypothesis that the use of Bupivacaine does not alter the protective effect of antibiotic coating. We examined if the zone of inhibition (ZOI) against E. coli created by InhibiZone in AMS and/or by Rifampin/Gentamicin soaked Coloplast implant is altered by Bupivacaine.
METHODS: E. coli was spread on LB agar plates. After a 30 minute incubation, 4 AMS InhibiZoneÒ strips treated with saline or Bupivacaine (1 mg/ml) were placed on a plate. 4 Coloplast strips were dipped in various routinely used concentrations of Rifampin (0 e 10 mg/ml) plus Gentamicin (0 e 1 mg/ml) solution with or without Bupivacaine (1 mg/ml). Following 24 h and 48 h incubation, ZOI was measured using the ImageJ software. Normalized ZOI was calculated as (ZOI area/plate area) x 100. Unpaired t-test compared the mean AE SD ZOI between Bupivacaine and no Bupivacaine groups (n [ 4/ group).
RESULTS: AMS with InhibiZoneÒ and Coloplast dipped in RþG combination inhibited E. coli growth following 24 h and 48 h incubation similarly. Coloplast strips dipped in RþG produced ZOI in a dose-dependent manner. The ZOI produced by AMS with InhibiZoneÒ was comparable to Coloplast strips dipped in 1.25 mg/ml R plus 0.125 mg/ml G. For both implants, addition of Bupivacaine did not affect ZOI both at 24 h and 48 h incubation. AMS with InhibiZoneÒ had a ZOI with and without Bupivacaine of 1.34 AE 0.06 and 1.21 AE 0.11 (p-value 0.062) at 24 h. For Coloplast 2.5/0.25 RþG combination showed a ZOI with and without Bupivacaine of 2.81 AE 0.42 and 2.2 AE 0.5 (p-value 0.122) at 24 h. This concentration of RþG was chosen since the ZOI produced was in the linear range and was the median of the various amounts used clinically.
CONCLUSIONS: Bupivacaine did not impede the antibacterial activity of InhibiZoneÒ or Rifampin/Gentamicin soaked Coloplast. This suggests the use of Bupivacaine does not affect the protective effects of antibiotic dips and can be used during implant operation. Whether the in vitro findings, translate to surgical outcomes needs to be evaluated.
Source of Funding: none

PD44-05 POPULATION LEVEL TRENDS IN THE SURGICAL TREATMENT OF PEYRONIE'S DISEASE: OVER USE OF PENILE PROSTHESES? ; UNDER USE OF PLAQUE INCISION AND GRAFTING?
Shyam Sukumar*, Debduth Pijush, Stanley Desire, Steven Brandes, New York, NY INTRODUCTION AND OBJECTIVES: Numerous surgical options exist for the treatment of Peyronie's disease (PD). The majority of prior reports on the surgical management of PD are from high volume centers or single surgeon series. There is a paucity of population-based data on the surgical management of PD.
METHODS: The New York Statewide Planning and Research Cooperative System database-a large statewide database that captures comprehensive all-payer data on patients across all outpatient and inpatient settings-was reviewed to identify patients with PD undergoing surgery from [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] [2016] . Descriptive statistics and multinomial regression modeling was used.
RESULTS: 1399 patients underwent surgical treatment for PD. Median age was 60 years, 52% of patients were Caucasian, and 45.9% had concurrent erectile dysfunction (ED). The most commonly performed procedures were penile prosthesis (PP) alone or as a combination procedure (CP; defined as a PP with concurrent modeling, tunical plication-TP-or plaque incision/excision with grafting-PEG). Of all patients without ED, the most commonly performed procedure was still PP (alone or as CP; 34.6%); rates of TP and PEG were 34.5% and 30.8%, respectively.
The annual rates of these procedures is shown in Figure 1 . Over the course of the study period, relative rates of TP were stable, but there was a significant increase in the use of CP (p[0.009) CONCLUSIONS: Penile prosthesis is by far the most commonly performed primary procedure for PD in New York State, even in patients without ED. The high volume of PP use, along with its use in 35% of patients with normal erectile function suggests over utilization of PP. Plaque incision and grafting is indicated for significant deformity and normal rigidity, yet utilization was lowest of the treatments and decreasing,even in patients without ED. This suggests possible under use of plaque incision and grafting.
